Predictors for establishing recommended phase 2 doses: analysis of 320 dose-seeking oncology phase 1 trials

By Penel Nicolas  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 653-661

Springer Publishing Company

Access to resources Recommend Favorite

Expanded approval for buccal fentanyl not recommended.

By  

Inpharma, Vol. 1, Iss. 1638, 2008-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite

Justification of the starting dose as the main determinant of accrual time in dose-seeking oncology phase 1 trials

By Penel Nicolas   Leblond Pierre   Lansiaux Amélie   Clisant Stéphanie   Dansin Eric   Adenis Antoine   Bonneterre Jacques  

Investigational New Drugs, Vol. 28, Iss. 6, 2010-12 ,pp. : 839-843

Springer Publishing Company

Access to resources Recommend Favorite

Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer

By Strickler John   McCall Shannon   Nixon Andrew   Brady John   Pang Herbert   Rushing Christel   Cohn Allen   Starodub Alexander   Arrowood Christy   Haley Sherri   Meadows Kellen   Morse Michael   Uronis Hope   Blobe Gerard   Hsu S.   Zafar S.   Hurwitz Herbert  

Investigational New Drugs, Vol. 32, Iss. 2, 2014-04 ,pp. : 330-339

Springer Publishing Company

Access to resources Recommend Favorite

A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer

By Schelman William   Mohammed Tabraiz   Traynor Anne   Kolesar Jill   Marnocha Rebecca   Eickhoff Jens   Keppen Michael   Alberti Dona   Wilding George   Takebe Naoko   Liu Glenn  

Investigational New Drugs, Vol. 32, Iss. 2, 2014-04 ,pp. : 295-302

Springer Publishing Company

Access to resources Recommend Favorite